People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Enlaza Therapeutics, Inc. | — | Pharmaceuticals | Series C | $134.6M | $87.7M | 2021 |
| Valora Therapeutics, Inc. | — | Biotechnology | Series A | $13.0M | $67.8M | 2024 |
Sanford Madigan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sanford Madigan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Topper | 1 | 12 |
| Shelley Chu | 1 | 10 |
| Stephen Squinto | 1 | 8 |
| Tighe Reardon | 1 | 7 |
| Jay Lichter | 1 | 7 |
| Miguel Garcia-Guzman | 1 | 2 |
| Marcos Milla | 1 | 2 |
| Stefan Heller | 1 | 2 |
| Sergio Duron | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.